IRVING, Texas, May 15 /PRNewswire-FirstCall/ -- Carrington Laboratories, Inc. announced the District Court of the 160th Judicial District of Dallas County rendered a permanent injunction and final judgment in its favor against Tom O’Brien d/b/a the Center for Natural Healing, ordering the defendant, its agents, representatives, employees, officers, affiliated companies or entities to stop from engaging in distribution of materials or otherwise associating their activities with Carrington or any of its products. Carrington had filed a lawsuit against Mr. O’Brien in December 2006 alleging unauthorized use of Carrington’s Manapol(R) on a website operated by Mr. O’Brien. The website also contained libelous and disparaging statements regarding Carrington, Manapol(R) powder and the drug substance Acemannan that were fraudulently posted as a press release from the International Aloe Science Council (“IASC”).
“The activities of Mr. O’Brien and his website were infringing on Carrington’s good name and reputation and were disruptive to our branded business activities. We appreciate the court’s decision to put an end to this wrongful behavior,” commented Carlton E. Turner, PhD, Carrington’s president and chief executive officer.
The permanent injunction specifically commands Mr. O’Brien and his affiliates to “desist and refrain from: (a.) Printing, publishing, copying, distributing, or pasting any information regarding Carrington Laboratories or any products manufactured or distributed by Carrington Laboratories, Inc., including but not limited to Manapol and acemannan; (b.) Making representations or statements regarding Carrington Laboratories or any products manufactured or distributed by Carrington Laboratories, Inc., including but not limited to Manapol(R) powder and acemannan; (c.) Using or referring to the name Carrington Laboratories, Manapol(R) powder, or acemannan and; (d.) Making any negative representations or statements regarding Carrington or any products manufactured or distributed by Carrington, including but not limited to Manapol(R) powder, and Acemannan.”
The court order further commanded Mr. O’Brien and his affiliates to remove all previously printed, published, copied, distributed or pasted content regarding Carrington Laboratories or any products manufactured or distributed by Carrington Laboratories, including but not limited Manapol(R) powder and Acemannan from www.asktom-naturally.com or any other website under Mr. O’Brien’s control.
About Carrington
Carrington Laboratories, Inc. is an ISO 9001-certified, research-based, biopharmaceutical and consumer products company currently utilizing naturally-occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care, as well as to manufacture and market the nutraceutical raw material Manapol(R) and cosmetic raw material Hydrapol(TM). Carrington also manufactures and distributes a complete line of wound care products for the professional veterinarian through its Veterinary Medical Division (CarraVet(R) Advanced Wound Therapy Products for horses, dogs, cats and companion animals, EquineVet(TM) Advanced Wound Therapy for horses, and EquineSmart(TM) Wound Care for the horse owner). Carrington also manufactures and markets consumer products and manufactures quality products for other companies. Manufacturing operations comply with cGMP standards. DelSite Biotechnologies, a subsidiary of Carrington, is developing its proprietary GelSite(R) technology designed to provide controlled release of peptide and protein-based drugs. Carrington’s technology is protected by more than 130 patents in 26 countries. Select products carry the CE mark, recognized by more than 20 countries around the world. For more information, visit http://www.carringtonlabs.com .
Certain statements in this release concerning Carrington may be forward- looking. Actual events will be dependent upon a number of factors and risks including, but not limited to: subsequent changes in plans by the Company’s management; delays or problems in formulation, manufacturing, distribution, production and/or launch of new finished products; changes in the regulatory process; changes in market trends; and a number of other factors and risks described from time to time in the Company’s filings with the Securities & Exchange Commission, including the Form 10-K, filed April 2, 2007.
Carrington Laboratories, Inc.
CONTACT: Carlton E. Turner Chief Executive Officer of CarringtonLaboratories, Inc., +1-972-518-1300
Web site: http://www.carringtonlabs.com/
